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Abstract
Background: Prostate-derived Ets factor (PDEF) is expressed in tissues of high epithelial content including prostate, 
although its precise function has not been fully established. Conventional therapies produce a high rate of cure for 
patients with localized prostate cancer, but there is, at present, no effective treatment for intervention in metastatic 
prostate cancer. These facts underline the need to develop new approaches for early diagnosis of aggressive prostate 
cancer patients, and mechanism based anti-metastasis therapies that will improve the outlook for hormone-refractory 
prostate cancer. In this study we evaluated role of prostate-derived Ets factor (PDEF) in prostate cancer.
Results: We observed decreased PDEF expression in prostate cancer cell lines correlated with increased aggressive 
phenotype, and complete loss of PDEF protein in metastatic prostate cancer cell lines. Loss of PDEF expression was 
confirmed in high Gleason Grade prostate cancer samples by immuno-histochemical methods. Reintroduction of 
PDEF profoundly affected cell behavior leading to less invasive phenotypes in three dimensional cultures. In addition, 
PDEF expressing cells had altered cell morphology, decreased FAK phosphorylation and decreased colony formation, 
cell migration, and cellular invasiveness. In contrast PDEF knockdown resulted in increased migration and invasion as 
well as clonogenic activity. Our results also demonstrated that PDEF downregulated MMP9 promoter activity, 
suppressed MMP9 mRNA expression, and resulted in loss of MMP9 activity in prostate cancer cells. These results 
suggested that loss of PDEF might be associated with increased MMP9 expression and activity in aggressive prostate 
cancer. To confirm results we investigated MMP9 expression in clinical samples of prostate cancer. Results of these 
studies show increased MMP9 expression correlated with advanced Gleason grade. Taken together our results 
demonstrate decreased PDEF expression and increased MMP9 expression during the transition to aggressive prostate 
cancer.
Conclusions: These studies demonstrate for the first time negative regulation of MMP9 expression by PDEF, and that 
PDEF expression was lost in aggressive prostate cancer and was inversely associated with MMP9 expression in clinical 
samples of prostate cancer. Based on these exciting results, we propose that loss of PDEF along with increased MMP9 
expression should serve as novel markers for early detection of aggressive prostate cancer.
Background
Prostate cancer is the second leading cause of cancer
death in men. In the United States alone, 192,280 new
cases of prostate cancers were diagnosed in 2009 and
among them around 27,360 deaths occurred. One of the
biggest challenges we face in prostate cancer is determin-
ing if the cancer is aggressive. Conventional therapies
produce a high rate of cure for patients with localized
prostate cancer, but there is no cure once the disease has
spread beyond the prostate. Reduction in serum prostate-
specific antigen (PSA) levels has been proposed as an
endpoint biomarker for human prostate cancer interven-
tion. However, despite being the mainstay of prostate
cancer detection, the value of PSA screening is still
* Correspondence: hari.koul@ucdenver.edu
1 Program in Urosciences, Division of Urology-Department of Surgery, 
University of Colorado Denver School of Medicine, Denver Veterans 
Administrative Medical Center, and University of Colorado Comprehensive 
Cancer Center, Building P15 or RC2, C-317, 12700 E 19th Avenue, Aurora, CO 
80045, USA
Full list of author information is available at the end of the article© 2010 Johnson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Johnson et al. Molecular Cancer 2010, 9:148
http://www.molecular-cancer.com/content/9/1/148
Page 2 of 14debated. In particular, there is a growing concern regard-
ing the over diagnosis of potentially indolent disease [1].
Therefore, there remains an urgent need for more accu-
rate biomarkers to diagnose aggressive prostate cancer.
Thus, identification of new molecular markers/targets for
aggressive prostate cancer is important in order to
improve early detection of the aggressive disease and to
develop new therapeutic regimens.
Progression of prostate cancer from focal, androgen-
dependent lesions to androgen-independent, metastatic
cancer requires deregulation of growth control, invasive-
ness and cell motility. Abundant evidence demonstrates
roles for Ets transcription factors in many cancers includ-
ing prostate. Prostate-derived Ets factor (PDEF), first
described nine years ago as preferentially binding to the
noncanonical Ets core sequence GGAT [2], has recently
received considerable attention due to its potential
importance in regulating cell motility and invasion [3-5].
Recently, proteomic analysis of PDEF overexpressing cells
revealed 286 proteins in the PDEF-associated protein
complex in breast cancer [6]. Thus interaction of PDEF
with other partner proteins could help in finding their
role in maintenance of malignant phenotype. Published
literature concerning experimental manipulation of
PDEF expression is paradoxical and limited to tissues of
high epithelial content, notably prostate, breast, ovary
and colon [7,8]. PDEF expression has been both positively
[3,9] and negatively [10] correlated with breast cancer
grade at mRNA or protein levels. It is important to note
that PDEF mRNA and protein levels do not always corre-
late, which may have led to different conclusions in some
of the studies examining PDEF expression in primary
tumors. Turner et al. [4] found that introducing PDEF
into invasive breast cancer cell lines reduced their invad-
ing ability. Similarly, siRNA-mediated knockdown of
PDEF in MCF7 cells increased their ability to migrate in
the Transwell assay. Besides its role in cancer metastasis,
PDEF expression was also correlated with changes in the
actin cytoskeleton and focal adhesion localization, and
loss of cellular polarity. Ghadersohi et al. [10] silenced
PDEF expression in MCF7 cells, and found that such cells
showed greatly accelerated xenograft tumor formation in
SCID mice. By contrast, Gunawardane et al. [3] showed
that increasing expression of PDEF increased their ability
to migrate in a Transwell assay and stimulated colony for-
mation in soft agar. This group also identified a canonical
MAP kinase phosphorylation site at T50 (PAT50P) and
showed that mutation to alanine at this site abolished all
the effects they observed. To date there are few data avail-
able formally correlating PDEF expression in mainte-
nance of prostate malignant phenotype. Two published
studies, one with a prostate cancer cell-line [5] and
another with clinical samples from prostate [11] reached
opposite conclusions with respect to the role of PDEF in
prostate cancer. Clearly additional studies are necessary
to evaluate role of PDEF in prostate cancer biology.
In the current studies, we report here that PDEF
expression is lost, whereas MMP9 expression increased
with the aggressive behavior of prostate cancer. Overex-
pression of PDEF in PC3 cells strongly inhibits colony
formation, cell migration and invasion, and increased cell
adherence. Furthermore, re-introduction of PDEF in PC3
cells led to changes in actin cytoskeleton, altered focal
adhesion kinase activity, and reestablished cell polarity in
these cultures as indicated by induction of less invasive
spheroid-like structures in three-dimensional culture,
Moreover, PDEF expression downregulates MMP9
expression, and its promoter activity in PC3 cells. Thus,
consideration of both PDEF and MMP9 may have a better
prognosis value for determining the aggressive phenotype
of prostate cancer.
Materials and methods
Constructs and cell lines
All cell lines (PC3, LNCaP, and C4-2B) were purchased
from ATCC and maintained according to ATCC guide-
lines. Phoenix cells were grown in DMEM containing
10% fetal bovine serum. FLAG tag antibody was pur-
chased from Sigma (St. Louis, USA). PDEF and phospho
FAK antibodies were from Santa Cruz Biotechnology
(CA, USA). PDEF was cloned from PC3 cDNA with an
amino-terminal FLAG tag, and inserted into retroviral
vectors pBABE and the bicistronic vector QCXIX (Clon-
tech). The latter vector was modified to contain a wild-
type internal ribosome entry site to increase expression
from the second multiple cloning site, into which G418
resistance was cloned. Mutations were created using the
Quick-Change kit (Stratagene) according to the manufac-
turer's instructions. Oligonucleotide primers for PCR
were purchased from Integrated DNA Technologies.
Retrovirus production and infection
Phoenix cells were transfected with 2 μg DNA using
Effectene (Qiagen) according to the manufacturer's
instructions, and infection was followed according to
Phoenix™ Retrovirus Expression System (Orbigen Inc.).
After infection, cells were trypsinized, transferred to 150
mm dishes, and subjected to puromycin or G418 selec-
tion after 48 h incubation.
Thymidine incorporation
1 × 105 cells/well were plated in 12-well plates. 48 h later,
cells were exposed to medium containing1-3 μCi/ml 3H-
thymidine (Perkin Elmer) and incubated for 4 h. After 2
washes with cold PBS, cells were fixed in cold methanol
for 5 min followed by an additional methanol wash. Cells
were solubilized in 0.1% SDS/0.2 M NaOH and radioac-
tivity determined.
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attachment assays
Growth in soft agar was performed as described previ-
ously [12]. Invasiveness was determined by the method of
Repesh LA [13]. Cell migration through Transwell mem-
branes was performed identically, but without the use of
Matrigel. Wound healing assays were performed by mak-
ing a cruciform scratch in a confluent monolayer of cells.
Cells were washed, the medium replaced with serum-free
medium, and incubated for 48-72 h. Cells were fixed with
methanol, stained with Giemsa, and photographed.
Attachment assays were performed essentially by the
method of Turner et al. [4] using 96-well plates pretreated
overnight with fibronectin, Matrigel, or bovine serum
albumin at concentrations of 50 ng/ml, 100 ng/ml, and 10
mg/ml respectively.
Immunohistochemistry for PDEF and MMP9 expression on 
prostate tissue array slides
Tissue microarray slides containing 9 normal and 40
prostate cancer samples of varying pathological grade
were obtained from Imgenex Corporation, San Diego,
CA, 92121. Immuno histochemistry for PDEF and MMP9
was performed using the avidin-biotin complex method
previously described by Hsu et al. [14]. Expression of
PDEF and MMP9 were evaluated by analysis of micro-
scopic scans of each tissue. Expression was considered
high if greater than 60% of the scanned area scored posi-
tive, while expression was considered moderate if 40-60%
area scored positive, and expression was considered low if
less than 40% area scored positive.
Reverse transcription PCR
Total RNA was extracted using RNEasy mini kit (Qiagen).
1 μg of RNA was used to prepare cDNA using iScript sec-
ond strand cDNA synthesis kit (Bio-Rad). 100 ng of syn-
thesized cDNA was used for RT-PCR using forward 5-
TTGACAGCGACAAGAAGTGG-3 and reverse 5-
TCACGTCGTCCTTATGCAAG-3 for MMP9, forward
5-ACCACAGTCCATGCCATCAC-3 and reverse 5-
TCCACCACCCTGTTGCTGTA-3 for GAPDH. Tran-
scripts were separated by agarose gel electrophoresis.
Reporter assay
Cells were transfected with 1 μg of MMP9 luciferase
reporter vector along with 10 ng of Renilla luciferase
expression plasmid using Effectene (Qiagen, Valencia,
CA) according to manufacturer's instructions. Luciferase
activity was measured using the Dual luciferase kit (Pro-
mega Corporation, Madison, WI) with Monolight 2010
Luminometer (Analytical Luminescence laboratory, San
Diego, CA).
MMP Zymography
Zymogram for MMP9 activity was performed according
to Bernhard and Muschel [15] using conditioned
medium.
Three dimensional cell culture
PDEF overexpressing PC3 cells and respective vector
control cells were grown in growth factor reduced Matri-
gel for 10-12 days and then immunofluorescence staining
was performed according to Debnath et al. [16]
Morphology studies
Cell morphology was done on glass chamber slides by
immunofluorescence method. Vector control and PDEF
expressing cells were seeded on multi-chamber slide,
fixed with 4% formalin, permeabilized with 0.1% Triton-
X-100, blocked in 2% BSA, and change in actin cytoskele-
ton was examined by phalloidin staining as per the manu-
facturer's instructions (Molecular Probes, Eugene, OR).
Pictures were taken using Spin Disc Olympus confocal
microscope.
Western Blot analysis
Electrophoresis and blotting were performed as
described previously [17].
Statistical analysis
Statistical analyses for tissue culture studies were per-
formed using two-dimensional two sample variance T-
tests; For data from clinical specimens, statistical analysis
was performed using MANN - WHITNEY U: exact test.
p ≤ 0.05 was considered significant.
Results
PDEF expression is reduced during the transition from low 
grade to high grade prostate cancer
PDEF expression was evaluated by immunohistochemical
examination in tissue microarray slides containing 40
cores of prostate cancer and 9 cores of normal prostate.
Results presented in Figure 1 show that PDEF protein
expression is downregulated during the transition to
aggressive prostate cancer. As shown in Figure. 1A, high
levels of PDEF protein are present in normal prostate epi-
thelial cells as well as early stage prostate cancer. How-
ever, in high grade prostate cancer PDEF protein is
significantly decreased. Significant reduction in PDEF
expression was observed in all cores of prostate tumor
tissue with high Gleason grade (Gleason score greater
than 7) as compared to normal prostate tissue as well as
low grade prostate cancer (Gleason score of 7 or below).
Moreover, PDEF protein levels showed graded decrease
with increase in pathologically confirmed aggressive dis-
ease. Our results show that while 59 ± 3.6% tissue scored
positive for PDEF in low to moderate grade (Gleason 6 &
7) prostate cancer, and 33 ± 3.3% of the tissue scored pos-
itive for PDEF in moderately high grade (Gleason 8)
tumor, there was little or no expression of PDEF in very
high grade (Gleason 9 & 10) prostate cancer(Figure. 1B).
Antibody specificity for these assays was determined by
Immunofluorescence and Western blot analysis using
cells with and without PDEF expression (Figure S1, Addi-
tional file 1). In addition to clinical samples, we also eval-
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cancer cell lines with low to high aggressive behavior.
These results presented in Figure 1C show that PDEF is
expressed in LNCaP cells (a less aggressive prostate can-
cer cell line). However, PDEF expression is reduced in
more aggressive lineages of LNCaP cells (C4-2 and C4-
2B). Moreover, PDEF expression is completely lost in two
widely used aggressive prostate cancer cells (DU145 and
PC3 cells). Taken together, results of these studies dem-
onstrate that PDEF expression is decreased or lost in
prostate cancer cells with aggressive phenotype, and pro-
vide novel insights into the characteristics of PDEF pro-
tein expression in progression of prostate cancers.
Absence of PDEF protein expression in PC3 cells in our
studies is in apparent disagreement with previous report
[5] that showed PDEF expression in PC3 cells,. This dis-
crepancy could result from several causes: First, the anti-
body used in [5] could be more sensitive, such that they
Figure 1 PDEF protein expression in human prostate tissues and prostate cancer cell lines. A, Representative photo-micrographs of Immuno-
histochemical analysis of PDEF expression using prostate tissue micro-array slides (containing both normal and tumor samples of different grades) 
performed as described in Materials and Methods. B, Quantification of percentage staining for PDEF. C, Representative image showing Western blot 
analysis on prostate cancer cell lines using anti-PDEF antibody (left panel), and quantitation of the same data (right panel).
Johnson et al. Molecular Cancer 2010, 9:148
http://www.molecular-cancer.com/content/9/1/148
Page 5 of 14were able to detect even negligible amounts of PDEF. Sec-
ond PC3 cells change over various passages of culture and
media conditions, which could explain the differences.
Re-introduction of PDEF inhibited directional migration, 
decreased cell migration and anchorage independent 
growth in prostate cancer cells
To examine the effects of PDEF expression on cell motil-
ity, PC3 cells transduced with PDEF or mutant PDEF
T50A, or vector alone were assayed for their ability to
migrate through Transwell membranes as described in
materials and methods. Results presented in Figure 2A
indicate that both wild-type and mutant PDEF-trans-
duced cells were significantly inhibited in their ability to
migrate through Transwell pores. We also subjected cells
to an assay for persistence migratory directionality (in
vitro wound healing, Figure. 2B). Expression of either
PDEF or the T50A mutant inhibited the ability of PC3
cells to fill in gaps in a monolayer compared to vector
alone. These results demonstrated that PDEF signifi-
cantly interfered with ability of cells to maintain migra-
tory phenotype.
We next examined the effects of PDEF overexpression
on the ability of PC3 cells to form colonies in soft agar.
Expression of either PDEF or the T50A mutant equally
inhibited the ability of PC3 cells to form colonies in soft
agar (Figure. 2C) compared to vector alone.
To address the possibility that altered cell proliferation
contributed to the results of these assays, we measured
DNA synthesis (3H-thymidine incorporation) in control
and PDEF transfected PC3. Results of these studies (Fig-
ure. 2D) show that decreased clonogenic activity follow-
ing PDEF expression was not a consequence of decreased
DNA synthesis. These results demonstrated that PDEF
expression decreased clonogenic ability of the cells inde-
pendent of DNA synthesis. Moreover, in sharp contrast
to the effects of PDEF on anchorage independent growth,
PDEF expression did not significantly affect anchorage
dependent growth of prostate cancer cells in culture (data
not shown).
PDEF expression resulted in increased cell adhesion, 
altered cell morphology and decreased focal adhesion 
kinase activity in prostate cancer cells
Immunofluorescence studies of PDEF expressing cells
showed a rounded area of cleared fluorescence rather
than elongated track as seen on invasive vector control
cells (Figure. 3A). These results indicated that PDEF
expression resulted in alterations to actin cytoskeleton
and altered cell morphology. FAK is a non-receptor pro-
tein tyrosine kinase, associated with supramolecular focal
adhesion complexes. Focal adhesion complex assembly
and disassembly are critical for cell attachment and
movement [18]. The lack of morphologic polarity in
PDEF expressing cells as shown in Figure 3A raised the
possibility that PDEF may affect adhesion complex for-
mation. Moreover, in previous studies we observed that
FAK was non-phosphorylated in adherent cultures and
FAK phosphorylation was increased in suspension cul-
ture [19]. Therefore, we evaluated the effects of re-intro-
duction of PDEF in PC3 cells on FAK phosphorylation in
PC3 cells in suspension cultures. Results of these studies
revealed a significant reduction in FAK phosphorylation
in PDEF expressing cells grown in suspension culture
(Figure. 3B). These results demonstrated that PDEF
expression in PC3 cells resulted in decreased FAK activ-
ity, suggesting decreased focal adhesion formation.
Focal adhesion formation and its interaction with the
ECM play a central role in migration and invasion, since
increased adhesion makes cells less motile. To examine
this possibility, we directly measured the effects of PDEF
expression on adhesion of PC3 cells to various ECM sub-
strates. For these studies, PC3 cells transfected with
PDEF or vector alone were assayed for their ability to
attach to fibronectin or Matrigel-coated plastic surfaces.
Results presented in Figure 3C indicate that attachment
of PDEF-expressing cells to fibronectin-coated, Matrigel-
coated, or control (BSA treated) plastic was significantly
increased compared to vector-transduced cells. These
results are in contrast to the effects of PDEF in breast
cancer cells, where PDEF was shown to decrease adhe-
sion of the cells to fibronectin and matrigel [4]. Taken
together, these results suggest that PDEF mediated inhi-
bition of migration may occur through cytoskeleton dis-
organization and ECM interaction.
PDEF decreased invasion and inhibited expression of 
matrix metalloproteinase-9 (MMP9) in prostate cancer cells
To test the effects of PDEF on cell invasion, we examined
the effects of PDEF expression on the ability of PC3 cells
to invade simulated basement membrane in vitro, a phe-
notype correlated with aggressive behavior. Results pre-
sented in Figure 4A indicate that expression of either
PDEF or the T50A mutant inhibited the ability of PC3
cells to invade through Matrigel compared with vector
transfected control cells. In addition to transfection of
PC3 cells with PDEF, we also performed complementary
RNA interference (RNAi) experiments to reduce the
endogenous PDEF expression in prostate cancer cells that
express PDEF (LNCaP and C4-2B cells), and directly
evaluated the effects of decreased PDEF levels on inva-
sion and clonogenic activity of these cells. Results pre-
sented in Figure S2, Additional file 1 demonstrated that
SiRNA mediated knock-down of PDEF in these cells
resulted in an increased ability to form colonies in soft
agar and increased invasion through Matrigel basement
membrane. Taken together with rest of the results these
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prostate cancer metastasis.
Matrix metalloproteinases (MMPs) are a family of
enzymes whose function primarily relates to degradation
of extracellular matrix proteins, and are necessary for cell
invasion. Moreover increased MMP activity has been
associated with tumor metastasis. In our in vitro studies
we observed that only MMP9 was prominently active in
PC3 cells. Thus we set out to test the possible role of
MMP9 in mediating the effects of PDEF on cell invasion.
For these studies we evaluated the effects of PDEF
expression on MMP9 mRNA expression, promoter activ-
ity and enzymatic activity. As can be seen in Figure 4B
&4C, PDEF expression completely abolished MMP9
Figure 2 Effect of re-introduction of PDEF on directional migration, trans-well migration and anchorage independent growth in prostate 
cancer cells. A, Migration of PC3 cells expressing PDEF or PDEF T50A through Transwell membranes as described in Materials and Methods. B, PDEF 
overexpression decreases directional cell migration (in vitro wound healing migration of these cells). C, Representative photomicrographs from exper-
iments testing colony formation as described in Materials and Methods. D, 3H-thymidine incorporation in PC3 PDEF overexpressing cells measured as 
described in Materials and Methods. E, Relative expression level of PDEF in these cell lines. Asterisks indicate significance levels of p < 0.05 with respect 
to controls.
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cantly reduced MMP9 promoter activity in PC3 cells
compared to vector control. These data demonstrate
inhibition of MMP9 expression by PDEF, and for the first
time demonstrate regulation of MMP9 by any ETS tran-
scription factors. To further confirm the role of MMP9 in
modulating invasive behavior of prostate cancer cells, we
performed antibody-neutralizing experiments. For these
studies, we added MMP9 antibodies to the cells during
the invasion assay, and data showed that anti MMP9 anti-
body inhibited cell invasion in PC3 cells by ~70% as com-
pared to control IgG (Figure. 4D), further supporting the
role of MMP9 in mediating the invasive phenotype in
prostate cancer cells. Taken together these results dem-
onstrate that PDEF negatively regulates MMP9 expres-
sion and provide a possible mechanism of PDEF actions
in suppression of the invasive phenotype in prostate can-
cer.
PDEF expression in metastatic Prostate cancer cells results 
in phenotypic reversal and decreased migration in three 
dimensional cultures
To examine the effects of PDEF expression in a context
that more closely resembled in vivo settings, we assessed
the consequence of PDEF expression in PC3 cells on aci-
nar or spheroid formation in 3 D culture. Results pre-
sented in Figure 5 demonstrate that PDEF expressing PC3
cells formed spheroid-like structures in basement mem-
brane cultures, while most of the vector control cells form
irregular structures and projections emanating from
these structures that readily migrated and invaded the
basement membrane by 10-12 days of culture. Several
recent studies demonstrated inverse relationship between
spheroid formation with cell migration and invasion. Our
results show that re-introduction of PDEF in PC3 cells
resulted in re-establishment of cellular polarity leading to
inhibition of cell migration and reversal to less invasive
phenotypes.
Phosphorylation of PDEF and PDEF T50A
Since the T50A mutant had little or no effect on many of
the phenotypic features associated with aggressive behav-
ior, we asked whether the T50 phosphorylation site was a
major contributor to PDEF phosphorylation. PC3 cells
were transiently transfected with PDEF, the T50A
mutant, or empty vector, and labeled with 32P-phosphoric
acid. FLAG-PDEF immunoprecipitates were sequentially
analyzed by autoradiography and Western blotting. The
Figure 3 Effects of PDEF expression in prostate cancer cells on cell morphology, FAK phosphorylation and attachment to specific sub-
strates. A, Phalloidin staining of actin cytoskeleton in PDEF expressing and vector control cells. B, Decreased phophorylation of FAK in PDEF express-
ing cells growing in suspension culture. C, Representative photomicrographs from experiments testing attachment of PC3 cell expressing PDEF to 
either BSA or fibronectin or matrigel-treated plastic surface as described in Material and Methods; and quantitation of these data. Asterisks indicate 
significance levels of p < 0.05 with respect to controls.
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T50A is phosphorylated, suggesting that amino acids
other than T50 in the protein are kinase targets. Of inter-
est, we found in this experiment that elimination of
reducing agents during electrophoresis resulted in an
approximate doubling of PDEF's apparent molecular
weight (under reducing conditions about 45 kd), suggest-
ing that native PDEF exists as a disulfide complex with
another molecule(s). Overall, these findings suggest that
amino acids other than the MAPK phospho-acceptor site
at T50 in the protein could be possible targets for kinase,
and they might have essential regulatory mechanism for
invasion and migration. Thus, the T50A mutation does
not alter the functions of PDEF and PC3 cells can phos-
phorylate PDEF at other locations.
Figure 4 Effect of PDEF on invasion through Matrigel Matrix and MMP9 mRNA expression, MMP9 promoter activity and MMP9 enzymatic 
activity of prostate cancer cells. A, Invasion of PC3 cells expressing PDEF or PDEF T50A through Transwell membranes as described in Methods. B, 
RT-PCR showing MMP9 mRNA (left panel) and MMP9 enzymatic activity using gelatin Zymography (Right panel) was performed to determine the level 
of active MMP9. C, MMP9 promoter activity as determined by Luciferase reporter assay. D, Invasion of PC3 cells through a basement membrane matrix 
after blocking MMP9 using antibodies or overexpressing PDEF. Asterisks indicate significance levels of p < 0.05 with respect to controls.
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to high grade prostate carcinomas and is inversely 
associated with PDEF expression
To further test whether MMP9 expression correlated
with aggressive behavior of prostate cancer cells and to
test whether a correlation existed between MMP9 and
PDEF expression in human prostate cancer specimens,
we evaluated MMP9 expression in the same tissue
microarray slides containing 40 cores of prostate cancer
and 9 cores of normal prostate that were used for PDEF
expression analysis. Results presented in Figure 6A &6B
show that MMP9 expression is up-regulated during the
Figure 5 Effect of PDEF expression on cells grown in three dimensional cultures. A, representative images of three dimensional matrigel culture 
of PC3 cells with and without PDEF showing phenotypic reversal. Representative phase image obtained at various days in culture using 20X objective. 
B, Fluorescence microscopic images of PDEF PC3 cells and vector control cells after phalloidin and DAPI staining in 3 D cultures. C) Schematic depic-
tion of the effects of PDEF expression in Prostate cancer cells.
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sented in Figure. 6B, demonstrate that MMP9 protein
staining was observed predominantly (>60-80%) in high
grade prostate cancer cells (Gleason 8, 9 & 10), whereas
normal prostate cells had very little or undetectable levels
of MMP9 protein. Increased MMP9 protein expression
was observed in 38 cores of prostate tumor tissue
whereas 2 cores of prostate cancer had no positive stain-
ing for MMP9. For low grade prostate cancer (Gleason 7
or below) 21 ± 3% tissue scored positive for MMP9 (stain-
ing >40-80%) whereas for Gleason 8 to 10 it increased to
60 ± 9.3%. Combining all, these results indicate that there
is significant co-relation between the low MMP9 expres-
sion in normal tissue with high MMP9 in intermediate to
high Gleason prostate carcinoma.
Inverse relationship between PDEF and MMP9 expression 
in human prostate tissue
Our analysis of the PDEF and MMP 9 protein expression
data presented in Figure 1 and 6 revealed that in human
prostate tissue PDEF levels were lower in tumor samples
as compared to normal tissue, however this difference
reached a statistical significance only in prostate cancer
samples form Gleason 8 and above (Normal vs. Gleason 6
& 7 Grade: p = 0.3593; Normal vs. Gleason 8 Grade: p =
0.0176; Normal vs. Gleason 9 & 10 Grade: p < 0.001). By
contrast, we observed that MMP9 levels were higher in
tumor samples as compared to normal tissue. Again the
difference in MMP9 expression reached statistical signifi-
cance only in prostate cancer samples form Gleason 8
and above (Normal vs. Gleason 6 & 7 Grade: p = 0.1517;
Normal vs. Gleason 8 Grade: p = 0.0076; Normal vs.
Gleason 9 & 10 Grade: p < 0.001). These data are pre-
sented for each individual sample in Figure 7A.
Our regression analyses of these data reveal an inverse
correlation between PDEF and MMP9 levels (Figure 7B
and Table S1, Additional file 1). Thus, a decreased expres-
sion of PDEF in prostate cancer is associated with the
malignant phenotype, more aggressive tumor behavior,
and increased MMP9 expression.
Discussion
This is the first study to demonstrate loss of PDEF protein
expression in high grade prostate cancer as compared to
normal prostate as well as low grade prostate cancer tis-
sue; and phenotypic reversal of highly migratory, invasive
and aggressive prostate cancer cells to adherent polarized
and non invasive cells in three dimensional cultures upon
re-introduction of PDEF. We also show for the first time
regulation of MMP9 by PDEF, and a direct correlation
Figure 6 MMP9 protein expression in Human prostate tissues. A, Immunohistochemistry for Representative photo-micrographs of Immuno-his-
tochemical analysis of MMP9 expression using prostate tissue micro-array slides (containing both normal and tumor samples of different grades) per-
formed as described in Materials and Methods. B, Quantification of percentage staining for MMP9.
Johnson et al. Molecular Cancer 2010, 9:148
http://www.molecular-cancer.com/content/9/1/148
Page 11 of 14between loss of PDEF and increased expression of MMP9
high grade prostate cancer.
The ETS family is one of the largest families of tran-
scription factors with 27 genes in human chromosome.
The ETS family is present throughout the body and is
involved in a wide variety of functions including the regu-
lation of cellular differentiation, cell cycle control, cell
migration, cell proliferation, apoptosis (programmed cell
death) and angiogenesis. Multiple Ets factors have been
found to be associated with cancer, such as through gene
fusion including prostate cancer (2, 20-25). PDEF is selec-
tively localized to the tissues with high epithelial content
including prostate, and like other Ets family members has
been shown to have diverse biological functions including
tumor suppressor as well as tumor promoter functions.
Our results demonstrate loss of PDEF in high grade
prostate cancer as compared to low grade prostate cancer
as well as normal prostate tissue. Our results are unique
in a way that they demonstrate for the first time loss of
PDEF is associated with aggressive phenotype in prostate
cancer, and suggest that PDEF might serve as a potential
marker for distinguishing aggressive prostate cancer from
Figure 7 Relationship between PDEF and MMP9 expression in human prostate tissue: A, Expression of PDEF and MMP9 in individual sam-
ples B) Regression plot of the data presented in A. Data were collected from the immunohistochemistry performed for PDEF and MMP9 as de-
scribed for Figure 1 and 6. (Normal = red; Gleason 6 & 7 = blue; Gleason 8 = green; and Gleason 9 and 10 = black). By regression analysis, there is a 
significant 0.846 (UNITS) drop in MMP9 for every 1.0 (UNIT) increase in PDEF.
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trast to the previously published studies that concluded
over expression of PDEF in prostate cancer as compared
to normal prostate tissue [11]. It is important to point out
here that previous studies lumped together all cancer
samples and compared them with normal tissue, how-
ever, they did not attempt subset analysis of PDEF expres-
sion between low grade and high grade disease, which
could have resulted in different conclusions. Our conclu-
sion that PDEF expression is a favorable indicator in pros-
tate cancer is, however, in agreement with studies that
demonstrated a positive prognostic value of PDEF in
ovarian cancer[8].
Our results also show that re-introduction of PDEF in
aggressive prostate cancer cells resulted in decreased cell
migration, decreased directional migration as well as
decrease in clonogenic activity and converse was true
when we knocked down PDEF in prostate cancer cells
expressing PDEF (Figure S2, Additional file 1). These data
suggest PDEF might serve as a suppressor of tumor
migration and clonogenic activity. These results are in
agreement with the previous studies with various breast
and prostate cancer cells [5,7]. Our results are, however
in sharp disagreement with studies that suggested that
PDEF might promote migratory phenotype in breast can-
cer cells [3].
In order to become motile, cancer cells establish a
defined polarity in the direction of movement through
interaction between lamellipodia (a cytoskeletal actin
projection on mobile edge of the cells) and focal adhe-
sions that facilitate adhesion and migration of the cells.
We also observed distinct changes in cytoskeleton and
cell morphology associated with PDEF expression. We
also show for the first time in any system that that PDEF
expression increased cell adhesion, and resulted in a sig-
nificant reduction in FAK phosphorylation. In previous
studies we have shown an essential role for FAK in
aggressive phenotype in prostate cancer cells [19]. Thus
modulation of cytoskeleton organization and FAK activ-
ity by PDEF expression may provide potential pathways
by which PDEF modulates cell behavior. These results
extend previous observations in several cell types that
show SiRNA mediated knockdown of PDEF was associ-
ated with increased cell migration [3-5]. While the results
discussed so far point to the possible role of PDEF expres-
sion in modulating phenotypic behavior of cancer cells,
our studies, are the first to use three dimensional cultures
to actually demonstrate directly the effects of PDEF on
cellular polarity and spheroid formation. Results clearly
demonstrate that re-introduction of PDEF in aggressive
prostate cancer cells resulted in phenotypic reversal from
a disorganized, migratory and invasive cell growth to an
organized, non-migratory and non-invasive phenotype.
Chintala et al. reported that the formation of spheroids
is also linked to reduced invasion and expression and
activity of MMP9 [26]. Matrix metalloproteinases (MMP)
are a family of enzymes whose function primarily relates
to the degradation of extracellular matrix proteins, and
which are necessary for cell invasion. Our results pre-
sented here show that upon PDEF expression, prostate
cancer cells lose their ability to invade Matrigel in Boyden
chamber assays. These results are similar to the results
observed by Turner et al. in invasive breast cancer cells
[4]. However, to the best of our knowledge, our results
show for the first time that PDEF downregulates MMP9
expression, and its promoter activity in any cell type. We
observed that expression of PDEF in PC3 cells resulted in
loss of MMP9 mRNA expression, decrease in MMP9 pro-
moter activity and a significant reduction in the gelati-
nolytic activity. Thus our results again highlight a unique
property of PDEF that is distinct from other ETS factors.
We carried out additional studies to directly evaluate the
functional consequence of MMP9 activity in PC3 cells.
Results of these studies demonstrate that antibody medi-
ated neutralization of MMP 9 reduced the invasion of
PC3 cells through basement membrane matrix similar to
that observed upon PDEF expression. Overall these find-
ings provide for a mechanism by which PDEF expression
could modulate cell polarity and other aggressive behav-
ior.
Since we observed negative regulation of MMP9 by
PDEF and published results suggested that the activity of
MMP9 is associated with the progression and metastasis
of prostate cancer [27], we also evaluated MMP9 expres-
sion in the tissue microarray slides containing 40 cores of
prostate cancer and 9 cores of normal prostate that were
used for PDEF expression analysis. Our results demon-
strated an increase in MMP9 expression in high grade
prostate cancer, which is in agreement with the previous
studies [27]. We also observed an inverse correlation
between PDEF expression and MMP9 expression in these
samples. These results are in agreement with our findings
in tissue culture studies that demonstrated negative regu-
lation of MMP9 expression by PDEF. These results also
highlight the potential use of loss of PDEF expression and
increased MMP9 expression in early detection of aggres-
sive prostate cancer.
Conclusions
In summary results presented herein demonstrate for the
first time that PDEF, a member of Ets family, is lost in
high grade prostate cancer and decreased PDEF expres-
sion is associated with increased MMP9 expression. We
also provide direct evidence for the first time demon-
strating that PDEF expression results in phenotypic
reversal of aggressive prostate cancer cells in three
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Page 13 of 14dimensional cultures. Our studies also provide first dem-
onstration in any system of negative regulation of MMP9
expression by PDEF. Taken together, our studies suggest
that PDEF, by virtue of suppressing MMP9 expression
and by modulating the ability of cancer cells to form a
temporal structure required for migration and invasion,
may function as suppressor of tumor metastasis in pros-
tate cancer and perhaps other cancers. Our observation
of an inverse relationship between PDEF and MMP9
expression suggests that expression of PDEF along with
decreased MMP9 could help in early detection of aggres-
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